The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index; 3 of the 10 sources its claims cite were checked for support.
Editorial: Constructing the vascular or cardiac tissue and organoids: the combination of biomedicine and engineering
Open accessAbstract
EDITORIAL article Front. Cardiovasc. Med., 16 February 2024Sec. Cardiovascular Biologics and Regenerative Medicine Volume 11 - 2024 | https://doi.org/10.3389/fcvm.2024.1371074
Overview
CoChat Summary
## TL;DR
This editorial introduces a Research Topic on bioengineered vascular and cardiac tissues/organoids as promising strategies for cardiovascular disease, framed as a collaboration between biomedicine and engineering. It briefly summarizes three reviews and one original research article, highlighting scaffold-based small-caliber vascular grafts and cardiac microtissues as key directions.
## Key findings
- Traditional vascular grafts are described as limited by supply and complications from mechanical stress, inflammatory responses, and inconsistent remodeling; bioengineered vascular tissue may be remodeled by the host and “even grow with young patients.”
- The review by Leal et al. covers small-caliber vascular graft development, manufacturing techniques, materials, animal studies, and clinical trials, and the editorial states that a cell-free scaffold-based small-diameter TEVG made from biocompatible polymers “would meet the significant clinical demand.”
- Reyat et al. developed vascularized, chamber-specific cardiac microtissues using hiPSC-derived atrial or ventricular cardiomyocytes plus vascular sprouts from human blood vessel organoids; the resulting microtissues had gene expression, architecture, and electrophysiology comparable to in vivo-derived cardiac tissues.
- Pro-fibrotic stimulation in Reyat et al.’s microtissues recapitulated cardiac fibrosis, and the phenotype was reversible with a receptor inhibitor, suggesting utility for disease modelling and pharmacological screening.
## Methods
- Editorial overview of a Research Topic that includes three review articles and one original research article on bioengineered vascular tissue and bioengineered cardiac tissue.
- Summarizes published approaches rather than reporting a new study design; the text describes topics including scaffold-based grafts, ventricle biofabrication strategies, and bone marrow vasculature models.
- For the original work summarized, the paper describes combining hiPSC-derived atrial or ventricular cardiomyocytes with vascular sprouts from human blood vessel organoids to create chamber-specific cardiac microtissues.
## Limitations
- The editorial does not report original experimental limitations or quantitative outcomes for most of the summarized papers; only brief qualitative descriptions are given.
- Evident from the text: it is a high-level editorial summary, so many details about sample sizes, protocols, and statistical analyses are not stated in the paper.
- The editorial’s conclusions about promise for clinical treatment are aspirational and not supported here by direct outcome data from the editorial itself.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
3 Valid · 0 Not valid · 7 Not checked · 1 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In comparison, bioengineered vascular tissue has the potential to overcome the issues mentioned above, be remodeled by the host into native tissue, and even grow with young patients (11).”
§ Editorial: Constructing the vascular or cardiac tissue and organoids: the combination of biomedicine and engineering > Bioengineered vascular tissue
What the sources say
- Supportedcites [11] Naegeli, 2022, Bioengineering human tissues and the future of vascular replacement, Circ Res source
In “Conclusions and Predicted Clinical Applications of Emerging Technologies” (page not provided), the review says tissue-engineered vascular grafts have the potential to meet patients’ needs and discusses their remodeling by the host into native tissue and growth with young patients. The “Tissue-Engineered Vascular Grafts” section also identifies growth with a pediatric recipient as a potential advantage. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In comparison, bioengineered vascular tissue has the potential to overcome the issues mentioned above, be remodeled by the host into native tissue, and even grow with young patients (11).”
§ Editorial: Constructing the vascular or cardiac tissue and organoids: the combination of biomedicine and engineering > Bioengineered vascular tissue
What the sources say
- Supportedcites [11] Naegeli, 2022, Bioengineering human tissues and the future of vascular replacement, Circ Res source
The Conclusions and Predicted Clinical Applications section (page not provided) explicitly discusses the ability of tissue-engineered vascular grafts to be remodeled by the host into native tissue. It frames this as potential that still requires further development, consistent with the claim. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In comparison, bioengineered vascular tissue has the potential to overcome the issues mentioned above, be remodeled by the host into native tissue, and even grow with young patients (11).”
§ Editorial: Constructing the vascular or cardiac tissue and organoids: the combination of biomedicine and engineering > Bioengineered vascular tissue
What the sources say
- Supportedcites [11] Naegeli, 2022, Bioengineering human tissues and the future of vascular replacement, Circ Res source
The Abstract identifies limitations of traditional grafts and says tissue-engineered conduits offer potential benefits, particularly remodeling into host tissue. The Conclusions state that TEVGs could meet those needs and discuss the possibility of growth with young patients, while noting that this ability needs further study. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
In the paper
“However, the phenotype can be reversed by the receptor inhibitor, indicating the potential of cardiac microtissues in disease modelling and pharmacological screening.”
§ Editorial: Constructing the vascular or cardiac tissue and organoids: the combination of biomedicine and engineering > Bioengineered cardiac tissue
What the sources say
- Not matchedcites Reyat et al.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“Reyat et al. have developed a method to create vascularized and chamber-specific cardiac microtissues by combining atrial or ventricular cardiomyocytes from hiPSC with vascular sprouts from human blood vessel organoids.”
§ Editorial: Constructing the vascular or cardiac tissue and organoids: the combination of biomedicine and engineering > Bioengineered cardiac tissue
What the sources say
- Not matchedcites Reyat et al.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
4 more claims
Create a free account to see all 11 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 2
Citations
Cites
Langer, R., & Vacanti, J. P. (1993) · Science · doi:10.1126/science.8493529 · Cited by 9,893
Organogenesis in a dish: Modeling development and disease using organoid technologies
Lancaster, M. A., & Knoblich, J. A. (2014) · Science · doi:10.1126/science.1247125 · Cited by 2,931
Global effect of modifiable risk factors on cardiovascular disease and mortality
The Global Cardiovascular Risk Consortium (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2206916 · Cited by 909
Environmental factors in cardiovascular disease
Cosselman, K. E., Navas-Acien, A., & Kaufman, J. D. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.152 · Cited by 613
Engineering the multiscale complexity of vascular networks
O’Connor, C., Brady, E., Zheng, Y., Moore, E., & Stevens, K. R. (2022) · Nature Reviews Materials · doi:10.1038/s41578-022-00447-8 · Cited by 271
Vulnerable plaques and patients: state-of-the-art
Tomaniak, M., Katagiri, Y., Modolo, R., de Silva, R., Khamis, R. Y., Bourantas, C. V., Torii, R., Wentzel, J. J., Gijsen, F. J. H., van Soest, G., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa227 · Cited by 197
Challenges and opportunities for the next generation of cardiovascular tissue engineering
Cho, S., Discher, D. E., Leong, K. W., Vunjak-Novakovic, G., & Wu, J. C. (2022) · Nature Methods · doi:10.1038/s41592-022-01591-3 · Cited by 176
Bioengineering human tissues and the future of vascular replacement
Naegeli, K. M., Kural, M. H., Li, Y., Wang, J., Hugentobler, E. A., & Niklason, L. E. (2022) · Circulation Research · doi:10.1161/circresaha.121.319984 · Cited by 112
Organs-on-a-chip: a union of tissue engineering and microfabrication
Zhao, Y., Wang, E. Y., Lai, F. B. L., Cheung, K., & Radisic, M. (2023) · Trends in Biotechnology · doi:10.1016/j.tibtech.2022.12.018 · Cited by 93
Bioengineering approaches to treat the failing heart: from cell biology to 3D printing
Yadid, M., Oved, H., Silberman, E., & Dvir, T. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00603-7 · Cited by 83
Metadata
- Authors
- Sun, D., Katare, R., Sethu, P., Cheng, P., & Fan, Y.
- Affiliations
- Army Medical University (CN)
- University of Otago (NZ)
- University of Alabama at Birmingham (US)
- University of Electronic Science and Technology of China (CN)
- Chengdu Military General Hospital (CN)
- Corresponding author
- Sun, Dayu
- Venue
- Frontiers in Cardiovascular Medicine
- Publisher
- Frontiers Media SA
- Published
- 2024-02-16
- Volume
- 11
- Pages
- 1371074-1371074
- ISSN
- 2297-055X (ISSN-L)
- PMC
- PMC10904631
- OpenAlex
- W4391881117
- Semantic Scholar
- 798700c91c9067eb18a22d4f1c7b55472a062d58
- Cited by
- 0
- References
- 13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Cardiovascular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Keywords
- vascular tissue engineering, cardiac tissue engineering, organoids, cardiovascular regenerative medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Editorial: Constructing the vascular or cardiac tissue and organoids: the combination of biomedicine and engineering. https://app.cochat.ai/papers/10.3389/fcvm.2024.1371074
- The paper
- Sun, D., Katare, R., Sethu, P., Cheng, P., & Fan, Y. (2024). Editorial: Constructing the vascular or cardiac tissue and organoids: the combination of biomedicine and engineering. Frontiers in Cardiovascular Medicine. https://doi.org/10.3389/fcvm.2024.1371074
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.